Guobang Pharma, the global pharmaceutical manufacturer, gained a rapid momentum at the start of year 2022, with a 283.08% increase of the net cash flow from operating activities compared to the same period last year.
Guobang Pharma (Chinese: 国邦医药, 605507), one of the leading stocks of pharmaceutical stocks in China, recently unveiled its Q1 FY2022 Earning Report.
According the report, its revenue totalled at CNY 1.18 billion (USD 266.8 million), up 2.96% compared to the same period last year. The net income attributable to the parent was CNY 200 million, up 8.26% compared to the same quarter last year. The net income after deducting non-recurring gains and losses was CNY 197 million, up 8.32% compared to the same period last year.
The net cash flow from operating activities was CNY 68.5 million, an increase of 283.08% compared to the previous year.
Guobang Pharma, founded in 1996, is one of the leading enterprises in the pharmaceutical industry with a focus on pharmaceutical intermediates and industry chains for both human and animals. It markets its produrts worldwide.